The expression of OTUD-6A and its clinical significance in gastric adenocarcinoma

doi:10.3877/cma.j.issn.2095-7157.2022.01.019

Abstract

Abstract:

Objective

To explore the expression of OTUD6A in gastric adenocarcinomatissues, as well as its association with clinicopathological characteristics and prognosis.

Methods

Forty patients who underwent gastric adenocarcinomaradical correction were enrolled in this study.Carcinoma tissues were obtained from these patients.The normal tissue 5 cm away from tumor margin was used. The expression of OTUD6A was detected by immunohistochemistry in gastric tissues.

Results

The expression of OTUD6A was higher in gastric adenocarcinoma tissues than that of in adjacent normal tissues, and high expression of OTUD6A was related to the depth of tumor invasion, degree of differentiation and TNM stage (P<0.05).

Conclusions

OTUD6A is highly expressed in gastric adenocarcinomatissues and was related to the local depth of tumor infiltration, degree of differentiation and TNM stage. OTUD6A may play a role in the occurrence, development and invasion of gastric adenocarcinoma.

Key words: Gastric cancer, Deubiquitinating enzymes, OTUD6A

Jingju Li, Deliang Liu, Yuyong Tan. The expression of OTUD-6A and its clinical significance in gastric adenocarcinoma[J]. Chinese Journal of Gastrointestinal Endoscopy(Electronic Edition), 2022, 09(01): 36-40.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhwcnjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-7157.2022.01.019

https://zhwcnjdzzz.cma-cmc.com.cn/EN/Y2022/V09/I01/36

Figures/Tables 4

References 22

[1]	郑荣寿，孙可欣，张思维，等.2015年中国恶性肿瘤流行情况分析[J]．中华肿瘤杂志，2019，41(1)：19-28.
[2]	VanCutsem E, Sagaert X, Topal B，et al.Gastric cancer[J]．Lancet，2016，388(10060)：2654-2664.
[3]	Wang YQ, Zhang QY, Weng WW，et al.Upregulation of the Non-Coding RNA OTUB1-isoform 2 Contributes to Gastric Cancer Cell Proliferation and Invasion and Predicts Poor Gastric Cancer Prognosis[J]. Int J Biol Sci，2016，12(5)：545-557.
[4]	Zhong JL, Huang CZ.Ubiquitin proteasome system research in gastrointestinal cancer[J]．World J Gastrointest Oncol，2016，8(2)：198-206.
[5]	Ni Q, Chen J, Li X，et al.Expession of OTUB1 in hepatocellular carcinoma and its effects on HCC cell migration and invasion[J]．Acta Biochim Biophys Sin (Shanghai)，2017，49(8)：680-688.
[6]	Zhou H, Liu Y, Zhu R，et al.OTUB1 promotes esophageal squamous cell carcinoma metastasis through modulating Snail stability[J]. Oncogene，2018，37(25)：3356-3368.
[7]	Kim SY, Kwon SK, Lee SY，et al.Ubiquitin-specific peptidase 5 and ovarian tumor deubiquitinase 6A are differentially expressed in p53+/+ and p53-/- HCT116 cells[J]．Int J Oncol，2018，52(5)：1705-1714.
[8]	Inoue Y, Itoh Y, Sato K，et al.Regulation of Epithelial-Mesenchymal Transition by E3 Ubiquitin Ligases and Deubiquitinase in Cancer[J]．Curr Cancer Drug Targets，2016，16(2)：110-118.
[9]	Messick TE, Russell NS, Iwata AJ，et al.Structural basis for ubiquitin recognition by the Otu1 ovarian tumor domain protein[J]．J Biol Chem，2008，283(16)：11038-11049.
[10]	Atanassov BS, Koutelou E, Dent SY.The role of deubiquitinating enzymes in chromatin regulation[J]．FEBS Lett，2011，585(13)：2016-2023.
[11]	孟小琴，李云峰，周毅，等．过表达OTUD1对结肠癌细胞HCT116增殖和侵袭的影响及机制研究[J]．重庆医科大学学报，2018，43(5)：687-691.
[12]	Yuan L, Lv Y, Li H，et al.DeubiquitylaseOTUD3regulates PTEN stability and suppresses tumorigenesis[J]．Nat Cell Biol，2015，17(9)：1169-1181.
[13]	Kim Y, Kim W, Song Y，et al.Deubiquitinase YOD1 potentiates YAP/TAZ activities through enhancing ITCH stability[J]．Proc Natl Acad Sci USA，2017，114(18)：4691-4696.
[14]	Zhao B, Huang X, Zhang J，et al.Clinicopathologic factors associated with recurrence and long-term survival in node-negative advanced gastric cancer patients[J]．Rev Esp Enferm Dig，2019，111(2)：111-120.
[15]	Pan SW, Wang PL, Huang HW，et al.A Proposal of a Personalized Surveillance Strategy for Gastric Cancer：A Retrospective Analysis of 9191 Patients[J]．Gastroenterol Res Pract，2019，2019：3248727.
[16]	Zheng L, Wu C, Xi P，et al. The survival and the long-term trends of patients with gastric cancer in Shanghai，China[J]．BMC Cancer，2014，14：300.
[17]	陈东方，王新妹．影响胃癌根治术术后生存期的多因素分析[J]．中国现代医生，2018，56(13)：91-93.
[18]	金鑫，赵恩昊，曹晖，等．早期胃癌临床病理学特征与预后的关系[J]．外科理论与实践，2011，16(1)：58-62.
[19]	任磊，赵志鸿．进展期胃癌患者病理特征与预后相关因素分析[J]．现代医药卫生，2017，33(16)：2454-2456.
[20]	Hosoda K, Yamashita K, Katada N，et al.Preoperative tumor size is a critical prognostic factor for patients with Borrmann type III gastric cancer[J]．Surg Today，2015，45(1)：68-77.
[21]	Wang X, Wan F, Pan J，et al.Tumor size：a non-neglectable independent prognostic factor for gastric cancer[J]．J Surg Oncol，2008，97(3)：236-240.
[22]	Huang CM, Xu M, Wang JB，et al.Is tumor size a predictor of preoperative N staging in T2-T4a stage advanced gastric cancer？[J]．Surg Oncol，2014，23(1)：5-10.

组别/临床病理参数		病例(n)	OTUD6A蛋白		P值
组别/临床病理参数		病例(n)	高表达(%)	低表达(%)	P值
年龄(岁)					0.532
	<60	26	16	10
	≥60	14	10	4
性别					0.842
	男	22	14	8
	女	18	12	6
肿瘤直径(cm)					0.123
	<5	25	14	11
	≥5	15	12	3
分化程度					<0.05
	高	0	0	0
	中	14	6	8
	低	26	20	6
浸润深度					<0.05
	T1-T2	15	6	9
	T3-T4	25	20	5
淋巴结转移					0.532
	无	14	10	4
	有	26	16	10
远处转移					0.287
	无	38	24	14
	有	2	2	0
TNM分期					<0.05
	Ⅰ期	10	9	1
	Ⅱ期	14	4	10
	Ⅲ期	14	12	2
	Ⅳ期	2	1	1

组别/临床病理参数		病例(n)	OTUD6A蛋白		P值
组别/临床病理参数		病例(n)	高表达(%)	低表达(%)	P值
年龄(岁)					0.532
	<60	26	16	10
	≥60	14	10	4
性别					0.842
	男	22	14	8
	女	18	12	6
肿瘤直径(cm)					0.123
	<5	25	14	11
	≥5	15	12	3
分化程度					<0.05
	高	0	0	0
	中	14	6	8
	低	26	20	6
浸润深度					<0.05
	T1-T2	15	6	9
	T3-T4	25	20	5
淋巴结转移					0.532
	无	14	10	4
	有	26	16	10
远处转移					0.287
	无	38	24	14
	有	2	2	0
TNM分期					<0.05
	Ⅰ期	10	9	1
	Ⅱ期	14	4	10
	Ⅲ期	14	12	2
	Ⅳ期	2	1	1

组别/临床病理参数		5年生存率(%)	平均生存时间(月)	log-Rank检验	P值
年龄(岁)				2.189	0.139
	<60	61.5	57.0
	≥60	35.7	44.3
性别				0.075	0.785
	男	50.0	52.1
	女	55.6	53.1
肿瘤直径(cm)				2.847	0.092
	<5	64.0	57.1
	≥5	33.3	45.0
分化程度				0.770	0.380
	高	-	-
	中	64.3	56.6
	低	46.2	50.5
浸润深度				3.279	0.07
	T1-T2	71.4	64.3
	T3-T4	42.3	46.3
淋巴结转移				1.453	0.228
	无	64.3	61.6
	有	46.2	41.7
远处转移				5.134	<0.05
	无	55.3	54.3
	有	0.0	19.0
TNM分期				10.891	<0.05
	Ⅰ期	88.9	74.8
	Ⅱ期	53.8	54.2
	Ⅲ期	37.5	43.0
	Ⅳ期	0.0	19.0

组别/临床病理参数		5年生存率(%)	平均生存时间(月)	log-Rank检验	P值
年龄(岁)				2.189	0.139
	<60	61.5	57.0
	≥60	35.7	44.3
性别				0.075	0.785
	男	50.0	52.1
	女	55.6	53.1
肿瘤直径(cm)				2.847	0.092
	<5	64.0	57.1
	≥5	33.3	45.0
分化程度				0.770	0.380
	高	-	-
	中	64.3	56.6
	低	46.2	50.5
浸润深度				3.279	0.07
	T1-T2	71.4	64.3
	T3-T4	42.3	46.3
淋巴结转移				1.453	0.228
	无	64.3	61.6
	有	46.2	41.7
远处转移				5.134	<0.05
	无	55.3	54.3
	有	0.0	19.0
TNM分期				10.891	<0.05
	Ⅰ期	88.9	74.8
	Ⅱ期	53.8	54.2
	Ⅲ期	37.5	43.0
	Ⅳ期	0.0	19.0

Please choose a citation manager

Content to export